Spectranetics Appoints Todd C. Schermerhorn as Director
March 12 2015 - 3:01PM
The Spectranetics Corporation (Nasdaq:SPNC) today announced that
its Board of Directors has appointed Todd C. Schermerhorn to the
Board, effective March 12, 2015. The Board consists of eight
members following the appointment of Mr. Schermerhorn. Mr.
Schermerhorn will serve on the Audit Committee of the Board.
Mr. Schermerhorn served as Senior Vice President and Chief
Financial Officer of C.R. Bard, Inc. from 2003 until his retirement
in August 2012. Mr. Schermerhorn joined Bard in 1985 as a cost
analyst and has held various financial positions including
Controller of the Vascular Systems Division and Vice President and
Controller of the USCI division. In 1996, Mr. Schermerhorn was
promoted to Vice President and Group Controller for Bard's Global
Cardiology Unit. He was promoted to Vice President and Treasurer in
1998. Mr. Schermerhorn serves on the board of directors of Thoratec
Corporation.
"Todd has demonstrated expertise as a highly successful Chief
Financial Officer at a large market cap, publicly-held, leading
medical device manufacturer. With his depth of medical device
industry experience and financial expertise, we believe Todd will
be an outstanding addition to our Board of Directors and Audit
Committee," said R. John Fletcher, Chairman of The Spectranetics
Corporation's Board of Directors.
About Spectranetics
Spectranetics develops, manufactures, markets and distributes
single-use medical devices used in minimally invasive procedures
within the cardiovascular system. The Company's products are sold
in over 65 countries and are used to treat arterial blockages in
the heart and legs and in the removal of pacemaker and
defibrillator leads.
Spectranetics recently acquired AngioScore Inc., a leading
developer, manufacturer and marketer of cardiovascular, specialty
scoring balloons and the Stellarex drug-coated balloon platform
from Covidien.
The Company's Vascular Intervention (VI) products include a
range of laser catheters for ablation of blockages in arteries
above and below the knee as well as the AngioSculptĀ® scoring
balloon used in both peripheral and coronary procedures and the
Stellarex drug-coated balloon platform. The Company also markets
support catheters to facilitate crossing of peripheral and coronary
arterial blockages, and retrograde access and guidewire retrieval
devices used in the treatment of peripheral arterial blockages,
including chronic total occlusions. The Company markets aspiration
and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser
sheaths, dilator sheaths, mechanical sheaths and accessories for
the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com
CONTACT: COMPANY CONTACT
The Spectranetics Corporation
Guy Childs, Chief Financial Officer
(719) 633-8333
INVESTOR CONTACT
Westwicke Partners
Lynn Pieper
(415) 202-5678
lynn.pieper@westwicke.com
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Apr 2023 to Apr 2024